Cutaneous lymphocyte-associated antigen as a novel predictive marker of TNF-alpha inhibitor biological therapy in psoriasis

Experimental Dermatology

Volumn 22, Issue 3, 2013, Pages 221-223

  Jókai, Hajnalka ^a   Szakonyi, József ^a   Kontár, Orsolya ^a   Barna, Gábor ^a   Inotai, Dóra ^b   Kárpáti, Sarolta ^a   Holló, Péter ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Hungarian National Blood Transfusion Service   (Hungary)

Author keywords

Cutaneous lymphocyte associated antigen; Predictive marker; Psoriasis vulgaris; TNF alpha inhibitors

Indexed keywords

ADALIMUMAB; BIOLOGICAL MARKER; CUTANEOUS LYMPHOCYTE ASSOCIATED ANTIGEN; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANTIGEN EXPRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; FEMALE; FLOW CYTOMETRY; HUMAN; LETTER; MALE; PSORIASIS; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MEMBRANE GLYCOPROTEINS; PREDICTIVE VALUE OF TESTS; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875052028     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/exd.12093     Document Type: Letter

References (28)

1. Rosenblum H, Amital H. Autoimmun Rev 2011: 10: 563-568.
2. Sizto S, Bansback N, Feldman S R et al. Br J Dermatol 2009: 160: 1264-1272.
3. Yamanaka K, Dimitroff C J, Fuhlbrigge R C et al. J Allergy Clin Immunol 2008: 121: 148-157.
4. Ni Z, Walcheck B. Clin Immunol 2009: 133: 257-264.
5. Pont-Giralt M, Giménez-Arnau A M, Pujol R M et al. J Invest Dermatol 2006: 126: 227-228.
6. Ferran M, Giménez-Arnau A M, Bellosillo B et al. Eur J Dermatol 2008: 18: 647-650.
7. Sabat R, Philipp S, Höflich C et al. Exp Dermatol 2007: 16: 779-798.
8. Li Y Y, Zollner T M, Schön M P. Clin Dermatol 2008: 26: 527-538.
9. Santamaria Babi L F, Moser R, Perez Soler M T et al. J Immunol 1995: 154: 1543-1550.
10. Pastore S, Gubinelli E, Leoni L et al. Biologics 2008: 2: 687-697.
11. Quaglino P, Ortoncelli M, Comessatti A et al. Dermatology 2009: 219: 250-258.
12. Richetta A G, Mattozzi C, Salvi M et al. Eur J Dermatol 2011: 21: 344-348.
13. Singh T P, Schön M P, Wallbrecht K et al. Exp Dermatol 2012: 21: 228-230.
14. Holló P, Marschalkó M, Temesvári E et al. J Dermatol Sci 2005: 39: 131-133.
15. Sigmundsdottir H. Trends Pharmacol Sci 2010: 31: 239-245.
16. Nakayama F, Teraki Y, Kudo T et al. J Invest Dermatol 2000: 115: 299-306.
17. Prinz J C. J Eur Acad Dermatol Venereol 2010: 24(Suppl 6): 1-4.
18. Grinblat B, Scheinberg M. Semin Arthritis Rheum 2008: 37: 251-255.
19. Terajima S, Higaki M, Igarashi Y et al. Arch Dermatol Res 1998: 290: 246-252.
20. Exarchou S A, Voulgari P V, Markatseli T E. Scand J Rheumatol 2009: 38: 328-331.
21. de Gannes G C, Ghoreishi M, Pope J et al. Arch Dermatol 2007: 143: 223-231.
22. Langewouters A M, van Erp P E, de Jong E M. Arch Dermatol Res 2008: 300: 107-113.
23. Davison S C, Ballsdon A, Allen M H et al. Exp Dermatol 2001: 10: 280-285.
24. McFadden J P, Baker B S, Powles A V et al. Br J Dermatol 2009: 160: 929-937.
25. Fry L, Baker B S. Clin Dermatol 2007: 25: 606-615.
26. Prinz J C. Hautarzt 2009: 60: 109-115.
27. Diluvio L, Vollmer S, Besgen P et al. J Immunol 2006: 176: 7104-7111.
28. Chen X, Oppenheim J J. FEBS Lett 2011: 585: 3611-3618.